These patients had significantly (p < 0.01) higher levels of TNF-α, IL-6, IL-17, IL-23 and TGF-β than those without BT, regardless of whether or not they had NAFLD. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.